Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome

Status Completed

Clinical Trial Summary

Obstructive sleep apnoea syndrome (OSAS) is characterised by repeated episodes of upper airway occlusion during sleep.It can cause cycles of hypoxia reoxygenation. And it was postulated that intermittent hypoxia seems to resemble ischemia-reperfusion.Many study suggest that ischemia-reperfusion represents an oxidative stress causing increased generation of reactive oxygen species, especially superoxide anions.It is one of the most important mechanisms of cardiovascular diseases, including hypertension, coronary artery disease and cerebrovascular accident complication with OSAS.So many individuals approve OSAS is an Oxidative Stress disease.

Continuous positive airway pressure (CPAP) is the first-line of treatment method in moderate/severe OSA.But poor adherence to CPAP treatment is very common.The failure rate with CPAP treatment is more than 50%.So we are searching a new treatment for that patients. Carbocysteine is a antioxidant.It can not only scavenges the free radicals but also replenishes glutathione(GSH)which is has double antioxidant capacity. However, Carbocysteine is cheaper than other which has double antioxidant capacity drugs,such as N-acetylcysteine.The purpose is to evaluate efficacy of oral intake of Antioxidant Carbocysteine witch can reduce oxidative stress and improve the symptom of OSAS.It recover the imbalance in the oxidant-anti-oxidant status may reduce cardiovascular abnormalities in Patients with OSAS.

Clinical Trial Description

OSAS patients are required to fill in questionnaire.And Inflammation biomarkers and Oxidative Stress biomarkers and ultrasonic will be tested.Then patients are randomly allocated to one of two groups. One group is treated with oral intake of Antioxidant Carbocysteine 500mg tid. The second group is treated with CPAP. After 6 weeks treatment, all patients will take the overnight polysomnogram test again, and take questionnaire, blood , ultrasonic test. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02015598
Study type	Interventional
Source	Guangzhou Institute of Respiratory Disease
Contact
Status	Completed
Phase	N/A
Start date	December 2013
Completion date	May 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01620554` - Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)	Phase 2
Not yet recruiting	`NCT01985347` - The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study	N/A
Completed	`NCT01312558` - The Effect of the Mediterranean Diet on Obstructive Sleep Apnoea-Hypopnoea Syndrome: A Randomised Trial	N/A
Completed	`NCT02967536` - Investigating the Neuropathology of Obstructive Sleep Apnoea
Completed	`NCT02855515` - Drug-Induced Sleep Endoscopy for the Optimisation of Treatment of Patients With Obstruction Sleep Apnoea	N/A
Terminated	`NCT03127800` - Morphine in Moderate Obstructive Sleep Apnoea	Phase 3
Recruiting	`NCT04262986` - A Brief Lifestyle Modification Programme in Overweight Subjects With Obstructive Sleep Apnoea - Needs Assessment
Completed	`NCT03145129` - PAIR Study-PAP And IOP Relationship: Study 2
Completed	`NCT02713152` - Prevalence of Obstructive Sleep Apnoea in Glaucoma	N/A
Completed	`NCT06376305` - EndoBarrier in Obstructive Sleep Apnoea Study	N/A
Completed	`NCT01661712` - Continuous Transcutaneous Electrical Stimulation in Sleep Apnoea	N/A
Terminated	`NCT01530451` - Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients	Phase 3
Completed	`NCT02518633` - Obstructive Sleep Apnoea and Adipose Tissue Dysfunction	N/A
Completed	`NCT01557166` - Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea	Phase 3
Recruiting	`NCT01829854` - To Investigate the Incidence of Obstructive Sleep Apnoea in Patient Undergoing Open Heart Surgery	N/A
Completed	`NCT01619748` - Peripheral Vascular Function in Obstructive Sleep Apnoea	N/A
Completed	`NCT02417584` - Efficacy of PAP Therapy on Blood Pressure	N/A
Completed	`NCT04071860` - Developing a Non-contact Sleep Apnoea Detector, Suitable for Home Studies- The Safescan Study
Not yet recruiting	`NCT04607343` - Clinical Trial of a Rehabilitation Device Based on Electrostimulation for Obstructive Sleep Apnoea	N/A
Completed	`NCT01546792` - Lifestyle Intervention in Obstructive Sleep Apnoea	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.